In reading this article you will understand:

  • How lung cancer is classified, the main risk factors, and why incidence and outcomes are changing in the UK.
  • How standard Critical Illness (CI) cancer definitions apply to lung cancer, including the distinction between invasive cancer and carcinoma in situ, and when additional payment wordings may be relevant.
  • How the NHS targeted lung cancer screening programme and increased use of low dose CT are shifting diagnoses to earlier stages, and what this means for CI claims.
  • Which clinical details and documents most help underwriting and claims teams to make faster, clearer decisions on cases involving lung cancer.

Each year, Lung Cancer Awareness Month gives us an opportunity to focus on a condition that remains the leading cause of cancer death in the UK, despite real progress in diagnosis and treatment. For advisers, it’s a timely moment to revisit how lung cancer is detected, managed and, crucially, how it is treated within Critical Illness (CI) policies. In this article, we shine a spotlight on lung cancer so you can better understand the medical landscape, the impact of targeted screening, and the practical implications for underwriting and claims.

 

The essentials: what lung cancer is and why it’s changing

Lung cancer broadly splits into two groups:

  • Non‑small cell lung cancer (NSCLC) – the commonest group
  • Small cell lung cancer (SCLC) – less common but faster growing.

Smoking remains the biggest risk (around 72% of UK cases), but air pollution, workplace exposures and radiation also contribute. Around four in five cases are considered preventable. Incidence patterns differ by sex and deprivation, and mortality has fallen over time as smoking rates have dropped and treatments improved.

Early detection is shifting: targeted screening

England’s targeted lung cancer screening (formerly Targeted Lung Health Checks, now the NHS Lung Cancer Screening Programme) invites eligible current and former smokers aged roughly 55–74 for a lung health check and, if risk is high, a low dose CT (LDCT) scan. The programme has now invited more than a million people and diagnosed over 5,500 lung cancers, more than three quarters at stage 1–2, compared with under 30% outside screening pathways. That stage shift matters for treatment options and survival.

LDCT itself is backed by large trials showing meaningful reductions in lung cancer mortality in high risk groups, which is why the NHS is rolling out screening nationally.

How CI policies cover lung cancer

All CI policies must cover cancer to at least the ABI minimum standard. For cancer, the ABI model wording pays for malignant tumours confirmed by histology with invasion into tissue; it excludes pre‑malignant changes and carcinoma in situ (CIS). In practice this means:

  • A diagnosis of invasive lung cancer (NSCLC or SCLC) will meet the core cancer definition and trigger a full payment.
  • Pre invasive disease (CIS) doesn’t trigger the core definition. Some policies offer an additional payment clause for CIS, often a catch all carcinoma in situ definition that requires surgical removal, so in rare early discoveries (which may increase with nearly introduced CT screening) a smaller payment may be possible, policy dependent.

Treatment at a glance

Treatment is decided by cell type and stage:

  • Early‑stage NSCLC: surgery (commonly lobectomy; sometimes segmentectomy or wedge for very small peripheral tumours), often followed by systemic therapy if risk is higher. Radiotherapy can substitute when surgery isn’t an option.
  • Locally advanced / metastatic NSCLC: combinations of chemotherapy, immunotherapy and targeted therapies.
  • SCLC: typically chemotherapy plus radiotherapy; surgery is less common because SCLC often spreads early.

For CI, none of the above treatment choices changes the basic rule: if it’s an invasive lung cancer, the core cancer definition pays.

Related CI definitions

As the main cancer definition is a full payment on diagnosis, the following alternative routes to claims are almost never seen.

  • Pneumonectomy (removal of a whole lung) and Lobectomy (removal of a lobe of the lung): some policies list this as a separate surgical trigger.

What screening means for claims

Screening is increasing the proportion of early stage, operable cancers. That’s good news medically and still squarely covered by CI under the core cancer definition because these are invasive tumours. It may also create occasional CIS finds, where cover depends on whether the policy includes a CIS additional payment definition that requires surgical removal. We can expect more “small, early, curable” invasive claims over time if screening uptake grows.

Plain‑English glossary you can use with clients

  • Carcinoma in situ (CIS): very early change in cells that hasn’t broken through the lining, non-invasive and usually excluded from the core cancer definition.
  • Invasive cancer: cancer cells have grown beyond the lining into lung tissue, meets the core cancer definition.
  • Lobectomy/segmentectomy/wedge resection: different extents of surgical removal; lobectomy is most common for curative surgery.

 

Underwriting: what helps to get a quick decision

If a client already has a history of lung cancer and is applying for insurance, send a concise pack up front. The following items are pure gold to underwriters:

  • Exact diagnosis: NSCLC (adenocarcinoma/squamous/other) or SCLC; site (lobe/bronchus).
  • Stage at diagnosis (TNM), grade.
  • Pathology/histology report summary confirming malignancy and margins after surgery (if applicable).
  • Biomarkers if tested (EGFR, ALK, ROS1, BRAF, KRAS, PD‑L1). These often drive treatment and prognosis.
  • Treatments and dates: surgery type (lobectomy/segmentectomy/wedge/pneumonectomy), chemo, radiotherapy, immunotherapy, targeted therapy; any adjuvant therapy (for example, osimertinib) and planned durations.
  • Response to treatment and most recent imaging (CT/PET‑CT) from follow ups.
  • Risk factors and modifications: smoking status/quit date, occupational exposures.
  • Follow up plan and disease free interval to date.

At claim: documents that speed payment

Claims teams can decide quickly when these are provided early:

  • Consultant respiratory/thoracic oncology letter confirming invasive lung cancer, histology and TNM stage.
  • Pathology report confirming malignancy and invasion (not CIS).
  • Imaging summaries (diagnostic and staging CT/PET‑CT) and MDT outcome.
  • Operation notes (if resection was done) or treatment plan for nonsurgical management.
  • Although unlikely, if claiming under a separate surgical trigger (for example, pneumonectomy) or transplant benefit, include the relevant operative or listing documents.
Protection Guru's Panel of Doctors

Things to reflect on for CPD:

  • How confident are you in explaining the difference between CIS and invasive lung cancer to clients, and how that affects CI payouts?
  • Do you routinely capture and submit the key clinical details listed to help underwriters and claims assessors?
  • What changes, if any, could you make to your client conversations to better link lifestyle risk factors (especially smoking) with protection planning and early detection?